Search Results

Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2024.

Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO) today announced that the Company will report its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, following the close of market.

Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the fourth quarter and full year ended December 31, 2023.

Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2023, on Monday, March 11, 2024.

Alpha Teknova, Inc., a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, launched the Company’s first custom product configurator, Build-TekTM Solutions, specifically created to address the need for fast turnaround, high-quality buffers for use during early-stage therapy development.